What's happened
A set of late-stage trials reports that a new experimental therapy outperforms current treatments in specific lung cancers, while Kisqali improves six-year survival when added to hormone therapy.
What's behind the headline?
Brief: Critical Perspective on Updates
- The landscape is shifting toward combination regimens that may redefine standard care for certain lung-cancer subtypes.
- Immunotherapy DLL3-targeted agents show promise as backbone therapies, potentially altering treatment sequences.
- Long-term survival signals are emerging for some combos, underscoring the need for broader access and real-world data.
What this suggests
- Expect regulatory reviews to accelerate for effective regimens; payers may adjust coverage to include combinations earlier in treatment.
- Hospitals will need to adapt through staffing, infusion capacity, and biomarker testing expansion.
- Patients could gain meaningful survival extensions, especially in extensive-stage disease, but results require longer follow-up for durability.
How we got here
Developments in lung-cancer treatment are advancing, with new immunotherapies and targeted therapies entering late-stage trials. The drugs cover non-small cell and small cell lung cancers, with trials spanning maintenance and combination strategies.
Our analysis
Bloomberg and CNBC report on Imdelltra plus Imfinzi, with UCLA-led Kisqali breast-cancer findings highlighted by Arab News and Bloomberg on six-year data; together they illustrate a broader shift toward targeted, combination therapies in oncology.
Go deeper
- What will new combinations mean for standard-of-care timelines?
- How will insurance coverage adapt to earlier use of these therapies?
- When will we see longer-term durability results publicly available?
More on these topics
-
Breast cancer - Cancer that originates in the mammary gland
Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include: a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin. Risk factors for developing breast cancer include obesity, a lack of physical exercise, alcohol consumption, hormone replacement therapy during menopause, ionizing radiation, an early age at first menstruation, having children late in life (or not at all), older age, having a prior history of breast cancer, and a family history of breast cancer. About five to ten percent of cases are the result of an inherited genetic predisposition, including BRCA mutations among others. Breast cancer most commonly develops in cells from the lining of milk ducts and the lobules that supply these ducts with milk. Cancers developing from the ducts are known as ductal carcinomas, while those developing from lobules are known as lobular carcinomas. There are more than 18 other sub-types of breast cancer. The diagnosis...
-
Dennis Slamon - American oncologist
Dennis Joseph Slamon (born August 6, 1948), is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25-33% of breast cancer patients and the..
-
European Society for Medical Oncology - Professional organisation
The European Society for Medical Oncology (ESMO) is a professional organisation for medical oncology. With more than 50,000 members representing oncology professionals worldwide, ESMO was founded in 1975.
-
Novartis - Pharmaceutical company
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is majority owned by American shareholders. It is one of the largest pharmaceutical companies by both market capitalization and sales. Novartis manuf
-
Madrid - Capital of Spain
Madrid is the capital and most populous city of Spain. The city has almost 3.3 million inhabitants and a metropolitan area population of approximately 6.5 million.
-
Amgen - Biotechnology company
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.